Pneumococcal vaccine GSK2189242A (formulation 2)

BIOLOGICAL2 trials

Sponsors

GlaxoSmithKline

Conditions

Infections, Streptococcal

Phase 2

Evaluation of a Booster Dose of Pneumococcal Vaccine Formulations in Young Adults

CompletedNCT00896064

GlaxoSmithKlineInfections, Streptococcal

Start: 2009-05-18End: 2009-08-05Updated: 2018-08-17

Safety & Immunogenicity of Pneumococcal Vaccine 2189242A in Children Aged 12-23 Months at the Time of First Vaccination

CompletedNCT00985751

GlaxoSmithKlineInfections, Streptococcal

Start: 2009-11-24End: 2011-03-02Updated: 2020-11-05

Related Papers

Safety and immunogenicity of an investigational vaccine containing two common pneumococcal proteins in toddlers: a phase II randomized clinical trial.

2014-04-0143 citations

Safety, reactogenicity and immunogenicity of a novel pneumococcal protein-based vaccine in adults: a phase I/II randomized clinical study.

2014-03-0652 citations